- Home
- BRBR vs TBPH Comparison
BRBR vs TBPH Comparison
Compare BRBR & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRBR | TBPH |
|---|---|---|
| Founded | 2019 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 908.9M |
| IPO Year | 2019 | 2013 |
Fundamental Metrics
Financial Performance| Metric | BRBR | TBPH |
|---|---|---|
| Price | $12.56 | $16.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 6 |
| Target Price | ★ $36.63 | $18.40 |
| AVG Volume (30 Days) | ★ 3.9M | 628.4K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 279.13 |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $2,316,600,000.00 | $15,386,000.00 |
| Revenue This Year | $6.28 | $8.46 |
| Revenue Next Year | $5.81 | N/A |
| P/E Ratio | $20.34 | ★ N/A |
| Revenue Growth | ★ 16.05 | N/A |
| 52 Week Low | $7.82 | $10.82 |
| 52 Week High | $54.65 | $21.03 |
Technical Indicators
Market Signals| Indicator | BRBR | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 55.51 | 50.50 |
| Support Level | $11.94 | $16.80 |
| Resistance Level | $14.29 | $17.21 |
| Average True Range (ATR) | 0.64 | 0.07 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 45.09 | 30.00 |
Price Performance
Historical ComparisonAbout BRBR BellRing Brands Inc.
BellRing Brands Inc is a United States-based company engaged in providing nutrition-related products. Its brands, Premier Protein, Dymatize, and PowerBar provides various products including ready-to-drink protein shakes, powders and nutrition bars. The company's products are distributed through a diverse network of channel including club, food, drug and mass, eCommerce, convenience and specialty.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.